{"downloaded": true, "htmlmade": false, "full": {"id": "30249784", "source": "MED", "pmid": "30249784", "pmcid": "PMC6284215", "fullTextIdList": {"fullTextId": "PMC6284215"}, "doi": "10.1182/blood-2018-06-858613", "title": "Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.", "authorString": "Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.", "authorList": {"author": [{"fullName": "Perrot A", "firstName": "Aurore", "lastName": "Perrot", "initials": "A", "authorId": {"@type": "ORCID", "#text": "0000-0003-0131-8689"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Nancy, France."}}}, {"fullName": "Lauwers-Cances V", "firstName": "Valerie", "lastName": "Lauwers-Cances", "initials": "V", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epidemiology and Statistics Department, University Hospital, Toulouse, France."}}}, {"fullName": "Corre J", "firstName": "Jill", "lastName": "Corre", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0003-1580-6106"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France."}, {"affiliation": "Universit\u00e9 Paul Sabatier, Toulouse, France."}]}}, {"fullName": "Robillard N", "firstName": "Nelly", "lastName": "Robillard", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Laboratory, University Hospital, Nantes, France."}}}, {"fullName": "Hulin C", "firstName": "Cyrille", "lastName": "Hulin", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Bordeaux, France."}}}, {"fullName": "Chretien ML", "firstName": "Marie-Lorraine", "lastName": "Chretien", "initials": "ML", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Dijon, France."}}}, {"fullName": "Dejoie T", "firstName": "Thomas", "lastName": "Dejoie", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Biochemistry Laboratory, University Hospital, Nantes, France."}}}, {"fullName": "Maheo S", "firstName": "Sabrina", "lastName": "Maheo", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France."}, {"affiliation": "Universit\u00e9 Paul Sabatier, Toulouse, France."}]}}, {"fullName": "Stoppa AM", "firstName": "Anne-Marie", "lastName": "Stoppa", "initials": "AM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Institut Paoli Calmettes, Marseille, France."}}}, {"fullName": "Pegourie B", "firstName": "Brigitte", "lastName": "Pegourie", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Grenoble, France."}}}, {"fullName": "Karlin L", "firstName": "Lionel", "lastName": "Karlin", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Lyon, France."}}}, {"fullName": "Garderet L", "firstName": "Laurent", "lastName": "Garderet", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Saint-Antoine University Hospital, Paris, France."}}}, {"fullName": "Arnulf B", "firstName": "Bertrand", "lastName": "Arnulf", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Saint-Louis University Hospital, Paris, France."}}}, {"fullName": "Doyen C", "firstName": "Chantal", "lastName": "Doyen", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Centre Hospitalier Universitaire (CHU) Universit\u00e9 Catholique de Louvain (UCL) Namur, Yvoir, Belgium."}}}, {"fullName": "Meuleman N", "firstName": "Nathalie", "lastName": "Meuleman", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Institut Jules Bordet (ULB), Brussels, Belgium."}}}, {"fullName": "Royer B", "firstName": "Bruno", "lastName": "Royer", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Amiens, France."}}}, {"fullName": "Eveillard JR", "firstName": "Jean-Richard", "lastName": "Eveillard", "initials": "JR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Brest, France."}}}, {"fullName": "Benboubker L", "firstName": "Lotfi", "lastName": "Benboubker", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Tours, France."}}}, {"fullName": "Dib M", "firstName": "Mamoun", "lastName": "Dib", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Angers, France."}}}, {"fullName": "Decaux O", "firstName": "Olivier", "lastName": "Decaux", "initials": "O", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Rennes, France."}}}, {"fullName": "Jaccard A", "firstName": "Arnaud", "lastName": "Jaccard", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Limoges, France."}}}, {"fullName": "Belhadj K", "firstName": "Karim", "lastName": "Belhadj", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Creteil, France."}}}, {"fullName": "Brechignac S", "firstName": "Sabine", "lastName": "Brechignac", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Bobigny, France."}}}, {"fullName": "Kolb B", "firstName": "Brigitte", "lastName": "Kolb", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Reims, France."}}}, {"fullName": "Fohrer C", "firstName": "Cecile", "lastName": "Fohrer", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Strasbourg, France."}}}, {"fullName": "Mohty M", "firstName": "Mohamad", "lastName": "Mohty", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Saint-Antoine University Hospital, Paris, France."}}}, {"fullName": "Macro M", "firstName": "Margaret", "lastName": "Macro", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Caen, France."}}}, {"fullName": "Richardson PG", "firstName": "Paul G", "lastName": "Richardson", "initials": "PG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Dana-Farber Cancer Institute, Boston, MA."}}}, {"fullName": "Carlton V", "firstName": "Victoria", "lastName": "Carlton", "initials": "V", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Adaptive Biotechnologies, Seattle, WA."}}}, {"fullName": "Moorhead M", "firstName": "Martin", "lastName": "Moorhead", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Adaptive Biotechnologies, Seattle, WA."}}}, {"fullName": "Willis T", "firstName": "Tom", "lastName": "Willis", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Adaptive Biotechnologies, Seattle, WA."}}}, {"fullName": "Faham M", "firstName": "Malek", "lastName": "Faham", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Adaptive Biotechnologies, Seattle, WA."}}}, {"fullName": "Anderson KC", "firstName": "Kenneth C", "lastName": "Anderson", "initials": "KC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Dana-Farber Cancer Institute, Boston, MA."}}}, {"fullName": "Harousseau JL", "firstName": "Jean-Luc", "lastName": "Harousseau", "initials": "JL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Clinique du Confluent, Nantes, France."}}}, {"fullName": "Leleu X", "firstName": "Xavier", "lastName": "Leleu", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Poitiers, France."}}}, {"fullName": "Facon T", "firstName": "Thierry", "lastName": "Facon", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Lille, France."}}}, {"fullName": "Moreau P", "firstName": "Philippe", "lastName": "Moreau", "initials": "P", "authorId": {"@type": "ORCID", "#text": "0000-0003-1780-8746"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Nantes, France; and."}}}, {"fullName": "Attal M", "firstName": "Michel", "lastName": "Attal", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, University Hospital, Toulouse, France."}}}, {"fullName": "Avet-Loiseau H", "firstName": "Herv\u00e9", "lastName": "Avet-Loiseau", "initials": "H", "authorId": {"@type": "ORCID", "#text": "0000-0002-3050-0140"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Myeloma Genomics Lab University Cancer Institute Toulouse (IUCT)-Oncopole, Cancer Research Center of Toulouse (CRCT), INSERM 1037, Toulouse, France."}, {"affiliation": "Universit\u00e9 Paul Sabatier, Toulouse, France."}]}}, {"fullName": "Munshi N", "firstName": "Nikhil", "lastName": "Munshi", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology Department, Dana-Farber Cancer Institute, Boston, MA."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-3050-0140"}, {"@type": "ORCID", "#text": "0000-0003-0131-8689"}, {"@type": "ORCID", "#text": "0000-0003-1580-6106"}, {"@type": "ORCID", "#text": "0000-0003-1780-8746"}]}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "23", "volume": "132", "journalIssueId": "2758271", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "2456-2464", "abstractText": "The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1\u2009000\u2009000 bone marrow cells (<10<sup>-6</sup>). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; <i>P</i> < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; <i>P</i> = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.", "affiliation": "Hematology Department, University Hospital, Nancy, France.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": {"grantId": "P50 CA100707", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Plasma Cells", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Bone Marrow", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm, Residual"}, {"majorTopic_YN": "N", "descriptorName": "Dexamethasone", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "High-Throughput Nucleotide Sequencing"}, {"majorTopic_YN": "N", "descriptorName": "Maintenance Chemotherapy"}, {"majorTopic_YN": "N", "descriptorName": "Bortezomib", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}]}, "chemicalList": {"chemical": [{"name": "Dexamethasone", "registryNumber": "7S5I7G3JQL"}, {"name": "bortezomib", "registryNumber": "69G8BD63PP"}, {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-06-858613"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6284215"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-06-858613"}]}, "commentCorrectionList": {"commentCorrection": {"id": "30523123", "source": "MED", "reference": "Blood. 2018 Dec 6;132(23):2424-2425", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "61", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-07-16", "dateOfCreation": "2018-09-26", "firstIndexDate": "2018-09-26", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-09-24", "firstPublicationDate": "2018-09-24", "embargoDate": "2019-12-06"}, "abstract": "The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1\u2009000\u2009000 bone marrow cells (<10<sup>-6</sup>). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; <i>P</i> < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; <i>P</i> = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.", "journaltitle": "Blood", "authorinfo": ["Perrot A", "Lauwers-Cances V", "Corre J", "Robillard N", "Hulin C", "Chretien ML", "Dejoie T", "Maheo S", "Stoppa AM", "Pegourie B", "Karlin L", "Garderet L", "Arnulf B", "Doyen C", "Meuleman N", "Royer B", "Eveillard JR", "Benboubker L", "Dib M", "Decaux O", "Jaccard A", "Belhadj K", "Brechignac S", "Kolb B", "Fohrer C", "Mohty M", "Macro M", "Richardson PG", "Carlton V", "Moorhead M", "Willis T", "Faham M", "Anderson KC", "Harousseau JL", "Leleu X", "Facon T", "Moreau P", "Attal M", "Avet-Loiseau H", "Munshi N"], "title": "Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma."}